Additionally, endorsing government policies of developed countries like US includes the Creating Antibiotics Opportunities Now (GAIN) Act to accelerate the approval process.
The development and introduction of antibiotics also facilitates the emergence of new diseases such as the Zika and Ebola virus.
Further, market participants are now generally introducing business strategies for joint growth to break the expenses.
Though, resistance production, particularly in the case of bacterial infections, is on the rise and making the antibiotic or its entire group ineffective, thus having a critical impact on the overall market growth.
However, HIV / AIDS, influenza, malaria, and tuberculosis are other infectious diseases known to pose high pressure.
Also, Resistance levels to increase over the forecast period 2020-2026 according to researchers, but can fluctuate depending on the pressure, geographies, and ethnicity of the patient.
Regional characteristics of Antibiotics Market size
North America and Asia Pacific to maintain a large proportion of the antibiotics market over the forecast period 2020-2026.
The healthcare system in the North American region encourages the use of branded goods, but with the loss to exclusivity of certain molecules, profits in this area have significantly eroded.
In American's region developed countries especially Brazil with its strong growth in the pharmaceuticals sector to show lucrative growth.
Factors driving the Asian Pacific region include the prevalence of numerous infectious diseases, favorable regulatory changes, population growth and unhygienic conditions resulting in bacteria resistant to antibiotics, and substantial demand for generic medicines.
Further, development of new antibiotics is important for the emergence of multi-resistance tuberculosis and methicillin-resistant Staphylococcus aureus (MRSA) infections.
In addition, increase in occurrence of pneumonia, blood stream infections, and Urinary Tract Infections (UTI) to promote the use of carbapenems class of antibiotics.
Advancements in R&D activities, product unveilings to contribute in antibiotics market share
New studies and launches by key market players to trigger the market growth. For instance, in 2020, French study finds anti-malarial and antibiotic combo to could reduce COVID-19 duration of the virus in patients.
Further, in 2020, Wockhardt became the first Indian pharmaceutical company to get the drug regulator's nod for two novel antibiotics.
As well, Hygiena in 2020 launched all-in-one Listeria Detection Method in which each device contains liquid media containing antibiotics.
In addition, in 2019, Researchers developed two new antibiotics that are effective against Gram-positive and negative multi-resistant bacteria.
Moreover, in 2019, The World Health Organization (WHO) launched a global campaign that urges countries to adopt its new online tool aimed at health workers to use antibiotics safely and more effectively.
Prominent companies in the antibiotics market include Pfizer, Inc., Janssen Pharmaceuticals, Abbott Laboratories, GlaxoSmithKline plc, Sanofi S.A., Novartis AG, Bayer AG; Bristol Myers Squibb Company, Eli Lilly and Company, and Astellas Pharma, Inc. among others.